Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) has shown promising results as an HCC-predictive biomarker. We aimed to develop and validate a PIVKA-II-based model for HCC risk stratification in cirrhotic patients with SVR to DAA.
Methods: A total of 1220 consecutive patients (Turin, n = 531; Pisa, n = 335; Milan, n = 354) with HCV-related cirrhosis treated with DAA were included in the study. Patients were retrospectively allocated to the training cohort (Turin+Pisa; median follow-up [FU] 39, 22-55 months; incident HCC: 93 [10.7%]) and validation cohort (Milan; median FU 49.0, 35.0-52.0 months; incident HCC: 19 [5.4%]). Serum PIVKA-II levels were measured using the LumipulseG system (Fujirebio, Japan) at SVR12 (Turin and Pisa cohorts) or the end of treatment (Milan cohort).
Results: Using Cox regression analysis, a model including PIVKA-II combined with age, sex, ALT, AST, γGT, platelet count, albumin and total bilirubin was derived from the training cohort (C-index = 0.72). In the validation cohort, the model showed a C-index of 0.71 with an area under the curve of 0.84 for identifying patients who developed HCC during the first 12 months of FU. When patients were grouped into three risk categories, the cumulative incidence of HCC was 2.7%, 4.0% and 14.3% in the low-, medium- and high-risk groups, respectively (p < 0.001). Notably, no HCC occurred within 3 years of FU in the low-risk group.
Conclusions: Our PIVKA-II-based model showed satisfactory accuracy for HCC risk stratification and may represent a valuable tool for implementing risk-based surveillance protocols in patients with HCV-related cirrhosis with SVR to DAA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707638 | PMC |
| http://dx.doi.org/10.1111/apt.18409 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic hepatitis C and the risk for atherosclerotic and cardiomyopathic heart disease.
World J Hepatol
August 2025
Department of Hospital Medicine, Hartford Hospital, Hartford, CT 06102, United States.
Hepatitis C virus (HCV) infection has been increasingly associated with cardiovascular complications, particularly atherosclerosis and cardiomyopathy, in addition to its primary hepatic effects. Studies indicate a higher prevalence of carotid atherosclerosis in patients with chronic hepatitis C infection, with viral load and steatosis emerging as independent risk factors. HCV-related atherosclerosis appears to develop through complex processes involving endothelial dysfunction, inflammation, oxidative stress, and immune dysregulation.
View Article and Find Full Text PDFCase Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features.
Front Oncol
August 2025
Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
Lymphoepithelioma-like cholangiocarcinoma (LEL-CC) is a rare variant of cholangiocarcinoma characterized by undifferentiated malignant epithelial cells and a significant lymphoid infiltrate. Due to its rarity, there is currently no established treatment protocol for LEL-CC, and limited data are available regarding the genomic landscape of this rare tumor. In this report, we present the case of an 84-year-old woman with a history of Hepatitis C-related cirrhosis who was diagnosed with EBV-negative LEL-CC.
View Article and Find Full Text PDFA Rare Case of Intravascular Large B-cell Lymphoma Presenting as Leukemic Phase in a Patient With HCV-Related Cirrhosis.
Cureus
July 2025
Internal Medicine, Northside Hospital Cherokee, Canton, USA.
We report a rare case of a 65-year-old man with decompensated cirrhosis due to alcohol and HCV, who presented with altered mental status, hypotension, and a diffuse rash. Laboratory findings were notable for leukocytosis, severe coagulopathy, and acute kidney injury. Peripheral smear and flow cytometry confirmed intravascular large B-cell lymphoma (IVLBCL), a rare and aggressive subtype of non-Hodgkin lymphoma characterized by intravascular proliferation of malignant lymphocytes.
View Article and Find Full Text PDFAssociation between glycemic control and hepatocellular carcinoma risk in people with type 2 diabetes, stratified by chronic hepatitis B or C infection.
Therap Adv Gastroenterol
July 2025
Department of Endocrinology and Metabolism, Chang Gung Memorial Hospital, 5, Fusing St., Guishan Dist., Taoyuan City 333, Taiwan.
Background: Chronic viral hepatitis is a major risk factor for hepatocellular carcinoma (HCC). Though diabetes is another risk of HCC, it remains indeterminant as to whether glycemic burden in individuals with type 2 diabetes (T2D) should be differentially managed according to the presence of chronic hepatitis B virus (HBV) or hepatitis C virus (HCV).
Objectives: To evaluate the association between glycemic burden and HCC risk in individuals with T2D, stratified by viral hepatitis status, including HBV and HCV.
Decline in Complications and Mortality in Chronic Liver Disease and Cirrhosis: A Population-Based Cohort Study From Northeastern Italy.
United European Gastroenterol J
July 2025
Epidemiological Department, Azienda Zero, Padova, Italy.
Background: Current trends in complications and mortality among individuals with chronic liver disease and cirrhosis are largely unknown.
Objective: To explore changes in mortality trends among patients with cirrhosis and chronic liver disease based on etiology in the Veneto Region (Italy), to differentiate mortality between liver-related and non-liver-related causes before and during the COVID-19 pandemic, and to determine trends in the development of cirrhosis complications.
Methods: Three subsequent population-based cohorts of individuals with chronic liver disease/cirrhosis were identified in Veneto (North-eastern Italy, 4.